Anzeige
+++Hot Stock!: China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?! China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?!+++
Hardman & Co Video Event

Shield Therapeutics (STX) Investor Forum 11.11.2024, 15:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Shield Therapeutics 0,057 EUR -30,49 % Stuttgart

Hardman & Co Research
Hardman & Co Video Event: Shield Therapeutics (STX) Investor Forum

11-Nov-2024 / 14:00 GMT/BST
The issuer is solely responsible for the content of this announcement.


Hardman & Co Video Event Shield Therapeutics (STX)

Investor Forum

We are delighted to announce that Shield Therapeutics (STX) will be presenting at Hardman & Co's upcoming Investor Forum at 3:00pm this Thursday 14 November 2024. Register for the event to secure your place and submit questions.

A commercial-stage pharmaceutical company, Shield Therapeutics is strategically positioned to address the significant unmet medical needs of patients suffering from iron deficiency. Since launching in the US in July 2021, Shield, alongside its partner Viatris, has successfully elevated physician awareness of ACCRUFeR®, a unique oral treatment for iron deficiency. This concerted effort has driven substantial sales growth. Diligent cost management underpins management’s confidence that its cash position, combined with anticipated growth, will support the trajectory toward cashflow breakeven. 

 

This interactive online Investor Forum comes at a crucial time. Presenting companies will address how their growth strategies and opportunity pipelines are set to perform in the post-budget environment, exploring the potential impacts and opportunities arising from the latest economic measures. The Forum promises to deliver valuable insights into how these businesses plan to leverage market conditions to sustain and drive growth.

This webinar represents a key communication channel for investors learn about company strategy and progress. All investors, whether existing shareholders or not, are invited to watch the presentation and take part in the Q&A session afterwards. There is no charge for attending. Investors are encouraged to submit their questions when registering or during the event. A recording of the webinar will be available on the Hardman & Co website shortly after the event for those who cannot attend the live presentation.

 

Register here: https://us06web.zoom.us/webinar/register/9817307129697/WN_3L26Tq96QOOiRRQQ5ivNfQ

To be first in the know about Hardman & Co’s latest digital events, subscribe to the mailing list here.

Our video events are designed to share the latest sector insights and company investment cases from our corporate clients and our expert team of analysts. Click here to subscribe to the Hardman Talks channel on YouTube.

Hardman & Co 9 Bonhill Street London EC2A 4DJ www.hardmanandco.com

Hardman & Co Research can be accessed for free after MiFID II.
Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies’ profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

2027145  11-Nov-2024 

fncls.ssp?fn=show_t_gif&application_id=2027145&application_name=news&site_id=boersennews_de~~~d41e2cc8-bdcb-47ba-bb51-c77a04513666
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer